Keros Therapeutics (KROS) Assets (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Assets came in at $338.0 million in Q4 2025, down 45.12% YoY from $615.9 million in Q4 2024, and down 54.49% on a QoQ basis from $742.8 million in Q3 2025.
Keros Therapeutics (KROS) Assets (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Assets data on file, last reported at $338.0 million in Q4 2025.
- Quarterly Assets fell 45.12% year-over-year to $338.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $338.0 million (down 45.12% YoY) and the FY2025 annual result came in at $338.0 million, down 45.12% from the prior year.
- Assets eased to $338.0 million in Q4 2025, from $742.8 million in the prior quarter.
- In the past five years, Assets ranged from a high of $784.6 million in Q1 2025 to a low of $226.7 million in Q2 2022.
- A 5-year average of $410.2 million and a median of $347.2 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2021 — Assets surged 325.35% — and 2025, when it plunged 45.12%.
- Tracing KROS's Assets over 5 years: stood at $255.3 million in 2021, then rose by 20.19% to $306.8 million in 2022, then advanced by 20.62% to $370.0 million in 2023, then jumped by 66.44% to $615.9 million in 2024, then sank by 45.12% to $338.0 million in 2025.
- The last three Assets figures came in at $338.0 million (Q4 2025), $742.8 million (Q3 2025), and $757.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Keros Therapeutics | 217.21 Mn | -40.40 Mn | - | 287.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 287.60 Mn |
| Dec 31, 2025 | 338.02 Mn |
| Sep 30, 2025 | 742.78 Mn |
| Jun 30, 2025 | 757.17 Mn |
| Mar 31, 2025 | 784.56 Mn |
| Dec 31, 2024 | 615.89 Mn |
| Sep 30, 2024 | 579.27 Mn |
| Jun 30, 2024 | 455.02 Mn |
| Mar 31, 2024 | 485.82 Mn |
| Dec 31, 2023 | 370.03 Mn |
| Sep 30, 2023 | 326.25 Mn |
| Jun 30, 2023 | 356.31 Mn |
| Mar 31, 2023 | 384.44 Mn |
| Dec 31, 2022 | 306.78 Mn |
| Sep 30, 2022 | 252.55 Mn |
| Jun 30, 2022 | 226.66 Mn |
| Mar 31, 2022 | 235.14 Mn |
| Dec 31, 2021 | 255.25 Mn |
| Sep 30, 2021 | 229.96 Mn |
| Jun 30, 2021 | 243.46 Mn |